Rhelixa
Decoding Life, Creating Future.
Tokyo, Japan · Founded 2015
- Headquarters
- Tokyo
- Employees
- 11–50
- Founded
- 2015
- Business Model
- B2B
- Website
- rhelixa.com
- Last Round
- Series BAug 2024
- Rounds
- 2
About
Rhelixa is a Tokyo-based biotechnology company and leading provider of epigenomic analysis services, applying proprietary technologies to analyze genomic, epigenomic, transcriptomic, and metagenomic data for life science research and development. Founded in 2015, the company partners with pharmaceutical, food, and healthcare companies to dramatically improve the efficiency and accuracy of R&D through scientific consulting and bioinformatics services. Its tagline reflects its mission to decode biological information to advance personalized health, drug development, and longevity research.
Summary
Rhelixa is a Biotech company based in Tokyo, Japan, founded in 2015. Its most recent funding was a Series B round in Aug 2024. Investors include Global Brain.
Sign up to view the funding chart
Create a free account — you'll get 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Aug 2024
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...